AS1404

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2004-2008
02420042008

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Introduction: Gliomas are the most common primary brain tumour type in adults but survival times remain low, irrespective of… (More)
Is this relevant?
Review
2008
Review
2008
BACKGROUND Interrupting tumour blood flow and delivery of nutrients to cause tumour death is the aim of antiangiogenic and… (More)
Is this relevant?
2007
2007
BACKGROUND DMXAA (5,6-dimethylxanthenone-4-acetic acid; AS1404), a vascular disrupting agent currently in clinical trials… (More)
Is this relevant?
2007
2007
5,6-Dimethylxanthenone-4-acetic acid (DMXAA) (AS1404), a small-molecule vascular disrupting agent currently in clinical trial… (More)
  • figure 2
  • figure 1
  • figure 3
  • figure 4
  • table 1
Is this relevant?
2006
2006
5,6-Dimethylxanthenone-4-acetic acid (DMXAA) (AS1404) is a novel antitumour agent that selectively disrupts tumour vasculature… (More)
  • table 1
  • figure 1
  • figure 4
  • figure 2
  • figure 5
Is this relevant?
2006
2006
Aims: DMXAA (AS1404), a small-molecule vascular disrupting agent that has now completed Phase II clinical trial, induces… (More)
  • figure 1
  • figure 2
  • table 1
Is this relevant?
2006
2006
  • MJ McKeage
  • Journal of clinical oncology : official journal…
  • 2006
7102 Background: DMXAA (AS1404) is a small-molecule vascular disrupting agent, which in animal models shows additive or supra… (More)
Is this relevant?
2006
2006
  • Hani Gabra
  • Journal of clinical oncology : official journal…
  • 2006
5032 Background: DMXAA (AS1404) is a small-molecule vascular disrupting agent, which in animal models shows additive or supra… (More)
Is this relevant?
2006
2006
13076 Background: DMXAA (AS1404) is a small-molecule vascular-disrupting agent that selectively disrupts established tumor blood… (More)
Is this relevant?
2004
2004
The selective targeting of established tumor vasculature represents an attractive new anticancer drug strategy, distinct from… (More)
  • figure 2
  • table 1
Is this relevant?